What Is TB-500?

TB-500 is one of the most talked-about “healing peptides” in the US wellness and athletic-recovery world, usually mentioned in the same breath as BPC-157. But before you can make sense of any claim about what it does, costs, or whether you can legally get it, you have to answer a more basic question that the marketing tends to skip: what is TB-500, actually? The short version is that it is a lab-made peptide named after a fragment of a natural protein — and pinning down exactly which molecule is in the vial turns out to be the foundation everything else rests on.

What TB-500 actually is

TB-500 is a synthetic peptide — a short, manufactured chain of amino acids designed to copy the active part of a naturally occurring protein called thymosin beta-4. It is not something your body produces and it is not a plant extract or a vitamin. It is made in a lab.

The complication is that “TB-500” is really a product name, not a precise chemical definition, and different sources describe it differently. In most scientific and pharmacy references, TB-500 is the 7-amino-acid fragment Ac-LKKTETQ — the small “actin-binding” stretch (roughly residues 17 to 23) of the larger thymosin beta-4 protein, with a molecular weight around 889 daltons. That fragment was identified decades ago as the minimal sequence that reproduces much of the parent protein’s tissue-repair activity, which is why it became the thing labs synthesized and sold.

That said, you will also find vendors and articles claiming their “TB-500” contains the full 43-amino-acid thymosin beta-4 sequence, and others that conflate it with a different fragment of the protein. That inconsistency is not a footnote — it is the single most important thing to understand about this compound. Two vials labeled “TB-500” can plausibly contain different molecules at different purities. So the honest one-line definition is: TB-500 is the name for a synthetic peptide based on the active region of thymosin beta-4, most commonly the LKKTETQ fragment — but “what’s in the vial” is not standardized.

Note: This page is about establishing what the molecule is. The deeper question of whether it delivers specific benefits is covered separately on the benefits page, and the head-to-head with its frequent partner BPC-157 lives on the comparison page.

Where it comes from: thymosin beta-4

To understand TB-500, you have to understand its parent. Thymosin beta-4 (often written Tβ4 or TB4) is a natural protein made up of 43 amino acids and encoded by the TMSB4X gene. It was first isolated from the thymus gland in the early 1980s and initially studied for immune-related roles, but it turned out to be one of the most abundant intracellular proteins in the body — present in nearly every cell, and especially concentrated in blood platelets, white blood cells, and the fluid at a wound site.

Its main biological job is regulating actin, the structural protein that lets cells hold their shape and crawl from place to place. Thymosin beta-4 acts as the principal “G-actin sequestering” molecule, maintaining a reservoir of actin building blocks that cells draw on when they migrate — which is exactly what cells need to do to close a wound or repair damaged tissue. That natural wound-context behavior is what sparked research interest in the first place.

TB-500 enters the picture as a deliberately stripped-down stand-in. By synthesizing just the short actin-binding motif rather than the whole 43-amino-acid protein, manufacturers get something far cheaper and easier to make that still carries the part believed to drive cell migration and tissue repair. The trade-off is that the fragment lacks the protein’s other functional regions — for example, it does not include the separate Ac-SDKP motif near the protein’s start, which is implicated in some of thymosin beta-4’s blood-vessel and cytoprotective effects. So TB-500 is not a smaller, equivalent copy of the protein; it is a selected piece of it.

What it’s studied for

The interest in TB-500 clusters around tissue repair and recovery. In research and in marketing, it is associated with:

• Soft-tissue and tendon repair — the most prominent claimed use, often in the context of stubborn tendon and ligament injuries.
• Muscle recovery — faster bounce-back from training or strain.
• Inflammation and wound healing — dialing down inflammatory signaling and supporting the repair phase.
• Angiogenesis — encouraging the new blood-vessel growth that healing tissue depends on.

It is also extremely commonly paired with BPC-157 in what the community calls the “Wolverine Stack,” on the theory that the two complement each other across different phases of healing. That combination has its own page; the key point here is that you almost never see TB-500 discussed in isolation, which matters a great deal when you try to judge whether it works.

These are the claimed and studied directions — not proven human outcomes. The next section is where the honesty comes in.

How it’s thought to work

The proposed mechanism is straightforward and biologically reasonable. By mimicking thymosin beta-4’s actin-binding region, TB-500 is thought to help cells reorganize their internal scaffolding and migrate more readily to sites of injury. Better cell migration plus encouragement of new blood vessels (angiogenesis) plus a damping of inflammatory signaling would, in theory, support a faster and more complete repair process across many tissue types.

The important caveat is that a plausible mechanism is not the same as a proven result. “This molecule binds actin and animal cells migrate better” is a hypothesis about why it might help. It is not evidence that injecting it into a person with a torn tendon produces a better outcome than rest and rehab would. Keep those two ideas separate, because the marketing routinely blurs them.

What the evidence actually shows

Here is the part that most “what is TB-500” explainers gloss over. The research record has a built-in gap that is easy to miss:

• Most human research is on the wrong molecule. The genuinely interesting human studies — corneal and ocular-surface healing, early cardiac-repair work, wound-closure trials — were largely conducted with full-length thymosin beta-4 (under names like RGN-259 and RGN-352), not the TB-500 fragment that people actually buy and inject. None of that work produced an approved product, and it does not automatically transfer to the fragment.
• The fragment’s own human evidence is essentially absent. There is no completed human efficacy trial and no published human pharmacokinetic data for the injected TB-500 fragment specifically. A 2025 orthopaedic scoping review looking for direct TB-500 evidence found very little; much of the fragment-specific literature is actually about anti-doping detection rather than benefit.
• The supportive data is mostly animal data. Tendon, muscle, and soft-tissue findings come predominantly from animal models. They are consistent and encouraging, but no adequately powered human trial has confirmed them.
• The stack confounds everything. Because TB-500 is so often run alongside BPC-157 and a real rehab program, separating its contribution from everything else is, in practice, impossible from anecdote.

So the accurate evidence summary is: a reasonable mechanism, suggestive animal data, human data that mostly belongs to a different (parent) molecule, and no direct human proof for the fragment itself. That is a long way from “proven.”

Its US legal status in 2026

TB-500’s legal standing in the US is genuinely confusing right now, partly because the regulatory picture changed in 2026 and the web is full of stale or contradictory claims. Here is the current state, which is accurate as of this page’s update date and may change:

• It is not FDA-approved for any indication. No product called “TB-500” has FDA approval.
• It was withdrawn from the FDA’s Category 2 list in April 2026. Some older pages describe it as “Category 2” (a substance flagged for safety concerns) or even claim it is now “Category 1” and freely compoundable. Neither is currently correct.
• It faces an FDA advisory review on July 23, 2026. TB-500 is among the peptides scheduled to go before the FDA’s Pharmacy Compounding Advisory Committee (PCAC), which will weigh whether it should be added to the 503A Bulk Drug Substances List — the list that would give licensed compounding pharmacies a clear, legal pathway to make it. That review is pending; nothing has been decided, and a favorable vote would still need formal rulemaking to follow.
• There is no clean compounding route in the meantime. Unlike BPC-157, TB-500 was always more of a research-chemical product than a pharmacy-compounded one, so even if the door opens later in 2026, its compounding supply chain would likely lag.
• It is banned in sport. The World Anti-Doping Agency prohibits TB-500 under category S2, so any athlete subject to drug testing should treat it as a banned substance.

The practical upshot: most TB-500 sold in the US today moves through “research only” vendors operating in a legal gray area, not through the regulated medical system. For a fuller picture of how the 2026 reshuffle happened, see the FDA peptide reclassification explainer and the broader are peptides legal in the US overview.

How people access it (legally)

Because the regulated pathway is unsettled, the legitimate-access picture for TB-500 is narrower than for many peptides. In broad terms, lawful access would run through a licensed provider who evaluates you and decides whether a compounded peptide is appropriate, with the medication dispensed by a licensed compounding pharmacy — the same telehealth-or-clinic model used across this space. The honest caveat is that, in mid-2026, a pharmacy may decline to fill a TB-500 prescription at all because of its uncertain compounding status, which is precisely the gap the July 2026 review is meant to address.

What is not a legitimate medical route is buying a “research only” vial online and self-injecting it. That bypasses any evaluation, leaves you with a product of unknown concentration and purity, and is the gray-market scenario the regulatory caution is built around. The mechanics of obtaining a legitimate prescription, and how the routes compare, are covered on the how to get TB-500 page rather than here.

If you’re trying to decide whether TB-500 belongs anywhere near your recovery plan, the realistic takeaway from “what is it” is this: it is a synthetic fragment with a believable mechanism, thin direct human evidence, an unsettled legal status, and a sport ban — a compound worth understanding carefully, and worth approaching through a real clinician rather than a checkout page.